Can You Survive Stage 4 Stomach Cancer in 2026?

Yes — even stage 4 (metastatic) stomach cancer can be managed with systemic chemotherapy and biomarker-matched treatment to keep the disease under control. The goal of treatment shifts from cure to control, but treatment itself does not stop.

Key Takeaways

• Treatment goals for stomach cancer differ by stage, and even at stage 4 (metastatic disease), there are reported cases of patients living for extended periods while the disease is kept under control with systemic chemotherapy.
• Korea's overall 5-year relative survival rate for stomach cancer is 78.6% (National Cancer Registration Statistics 2019–2023, National Cancer Center Korea Central Cancer Registry). This is an average across all stages 1 through 4 combined, not a stage-4-specific figure.
• For stage 4 stomach cancer, standard treatment now includes adding targeted agents or immune checkpoint inhibitors to chemotherapy, depending on biomarker results such as HER2, PD-L1, and CLDN18.2.
• Survival rates are population averages, not predictions for any individual outcome, and results vary greatly depending on stage, tumor histology, age, and coexisting conditions.

Is Treatment Still Possible at Stage 4?

• Yes. However, the goal of treatment shifts from cure to 'control.' For stage 4 or recurrent stomach cancer where surgery is not feasible or the disease has spread to other organs, systemic chemotherapy becomes the core treatment, and first-line drugs are selected based on test results for HER2, PD-L1, and CLDN18.2.
• If HER2-positive, a targeted therapy is added to chemotherapy; if PD-L1 expression is high, an immune checkpoint inhibitor is added — both are part of the standard treatment pathway. Radiation therapy is not a primary treatment for stomach cancer but may be selectively used to reduce bleeding, pain, or symptoms from bone or brain metastases.
• Whether and how long a patient survives varies from person to person depending on the site and number of metastases, biomarker results, overall health status, and treatment response. Outcomes vary widely even among patients at the same stage 4.

How Should Korea's Stomach Cancer Survival Figures Be Interpreted?

• Korea's 5-year relative survival rate for stomach cancer, 78.6%, is a national average that includes all stages 1 through 4 (National Cancer Registration Statistics 2019–2023). By comparison, the U.S. SEER 5-year relative survival rate for stomach cancer for the same type of period is 39.8% (2016–2022).
• Both figures are nationwide statistics, not results from any specific hospital, and much of the difference comes not only from treatment technology but also from the rate of early detection. Korea has a national screening program offering gastroscopy every two years starting at age 40, which leads to a relatively high rate of early-stage stomach cancer detection.
• A survival rate specific to stage 4 alone is not included in this reference material, so the overall average figure should not be directly applied as a predicted outcome for an individual stage 4 patient.

The Process From Diagnosis to Treatment for Stage 4 Stomach Cancer

• Step 1 — Gastroscopy and biopsy confirm whether cancer is present and identify the tumor histology (intestinal or diffuse type, degree of differentiation).
• Step 2 — Abdominal and chest CT scans assess the depth of wall invasion, lymph node involvement, and spread to other organs; PET-CT is selectively performed if metastasis is suspected.
• Step 3 — Biomarker testing for HER2, PD-L1, CLDN18.2, and MSI determines which drugs will be used for systemic chemotherapy.
• Step 4 — Chemotherapy tailored to biomarker results begins (combined with targeted therapy or immune checkpoint inhibitors as needed), with radiation therapy selectively added to relieve bleeding, pain, or metastatic symptoms.
• Step 5 — Follow-up continues at set intervals through clinic visits, blood tests, and CT scans, depending on treatment response.

FAQ — How Are Side Effects During Chemotherapy Managed?

• Chemotherapy can cause reactions that come and go with each cycle, including nausea and vomiting, mouth sores, hair loss, low white blood cell counts, and numbness in the hands and feet. About 70–80% of patients experience nausea and vomiting, which typically appear within 1 to 8 hours after administration and can last up to a week; low white blood cell counts usually begin around week 1, reach their lowest point at week 2, and recover by week 3 (National Cancer Information Center).
• If body temperature reaches 38°C or higher, or if chills are severe, patients should contact their medical team or visit an emergency room immediately, day or night. Most side effects generally resolve before the next cycle begins, but which symptoms require contact and when can vary by drug, so guidance from the treating medical team should be followed.

FAQ — Can a Treatment Plan Be Set Up in Korea Based on Test Results From Abroad?

• Yes. If you prepare imaging (original DICOM files such as CT scans), endoscopy findings, biopsy and pathology reports, biomarker test results (HER2, PD-L1, CLDN18.2, MSI), and your medication history to date (drug names, doses, number of cycles, and response), you can receive a written opinion on staging and treatment feasibility.
• The remote review (pre-arrival review) fee is KRW 1,000,000, and if you proceed to contract treatment after the review, this amount is deducted from your treatment costs. The required length of stay depends on the treatment method; for stage 4 chemotherapy, an option of receiving the first cycle in Korea and continuing the remaining cycles locally is also proposed along with an estimate.

Sources and Notes

• This article was written based on reference material on stomach cancer (National Cancer Registration Statistics 2019–2023 · National Cancer Center Korea, SEER 2016–2022, National Cancer Information Center, NCCN patient guidelines) and reference material on principles of managing chemotherapy side effects (National Cancer Information Center, U.S. National Cancer Institute, NCI).
• This content is provided for general medical information purposes only, and actual diagnosis, treatment methods, and outcomes may vary depending on individual circumstances. Please consult your medical team for an accurate diagnosis and treatment decision.